CTOs on the Move

OrthoTennessee

www.orthotn.com

 
OrthoTennessee provides the finest orthopedic clinics in East Tennessee, improving lives through patient-centered care, orthotics, therapy and imaging.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.orthotn.com
  • 256, Fort Sanders West Boulevard
    Knoxville, TN USA 37922
  • Phone: 865.769.4500

Executives

Name Title Contact Details

Similar Companies

Virtus Pharmaceuticals

Virtus Pharmaceuticals’ mission is to be the leading specialty niche pharmaceutical company providing the highest quality products through experienced leadership, innovative approaches and outstanding customer service.

Dauntless Pharmaceuticals

Dauntless Pharmaceuticals, Inc is a San Diego, CA-based biopharmaceutical company. The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share interest in all company assets. In contrast, Dauntless uses a one-asset, one-company model.

Chartiers Center

Chartiers’ primary focus is the integration of physical health and mental health wellness to enhance the quality of life for all people with behavioral or intellectual/ and developmental disabilities. Chartiers operates programs for adults with inte...

Healthstore Holdings

Our proprietary and vertically integrated technology solutions empower clients to improve patient outcomes and enhance medication adherence through improved access (virtual care and MTM), owned pharmacy infrastructure and physician network, information...

Dicerna

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.